Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2013 September;55(3) > Panminerva Medica 2013 September;55(3):269-75

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti

 

  EXCELLENCES IN DIABETES 

Panminerva Medica 2013 September;55(3):269-75

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

Closer to ideal insulin action: ultra fast acting insulins

Cengiz E.

Division of Pediatric Endocrinology and Diabetes, Yale School of Medicine, New Haven, CT, USA


PDF


Mimicking physiologic insulin action has been the main goal of diabetes therapy since the discovery of insulin. The evolution of insulin therapy from animal insulin to recombinant insulin analogs has improved diabetes treatment significantly over the course of years. Nevertheless, the rapid-acting insulin analog pharmacokinetics and pharmacodynamics are still far from replicating physiologic insulin action resulting in poorly controlled after meal blood glucose levels. The slow action of insulin analogs has been a stumbling block for the development artificial pancreas systems that require a fast responding insulin to blood glucose changes. This review explains the rationale behind the undeniable need for ultra-fast acting insulins from a clinical and research perspective and summarizes ongoing and future projects to accelerate insulin action.

inizio pagina